All In Biotech

Drug Trial Radar · NCT00135226

ASCEND: A Study of Cardiovascular Events iN Diabetes

A Study of Cardiovascular Events iN Diabetes - A Randomized 2x2 Factorial Study of Aspirin Versus Placebo, and of Omega-3 Fatty Acid Supplementation Versus Placebo, for Primary Prevention of Cardiovascular Events in People With Diabetes

Last checked: Nov 20, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 15,480 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

15,480

Actual

Start

Mar 2005

Primary completion

Mar 12, 2018

Study completion Jul 31, 2037

Sponsor

Lead sponsor
University of OxfordAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
British Heart Foundation; Bayer; Medical Research Council; Solvay Pharmaceuticals; Abbott; Mylan; Health Data Research UK; Alzheimer's Research UK; The Macular Society
First posted
Aug 25, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether 100mg daily aspirin versus placebo and/or supplementation with 1 gram daily omega-3 fatty acids or placebo prevents "serious vascular events" (i.e. non-fatal heart attack, non-fatal stroke or transient ischaemic attack, or death from vascular causes) in patients with diabetes who are not known to have occlusive arterial disease and to assess the effects on serious bleeding or other adverse events.

Conditions

  • Diabetes Mellitus

Interventions

  • AspirinDrug

  • Omega-3 Ethyl EstersDrug

  • Placebo AspirinDrug

  • Placebo Omega-3 Ethyl EstersDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With First Occurrence of Any Serious Vascular Event (SVE)Time frame: Randomized treatment phase during a mean of 7.4 years
  2. Number of Participants With First Occurrence of Any Major Bleed (Aspirin Comparison Only)Time frame: Randomized treatment phase during a mean of 7.4 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Service Unit, NDPH, University of Oxford

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.